Matthew Sharpe
Psychiatric/Mental Health · Penfield, NYNPI 1407052061
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,075 of the $59,327 with a category attached, or 81.0%. Johnson & Johnson accounts for 95.5% of it on its own, with 13 other manufacturers making up the rest. Among psychiatric/mental health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $240.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$57K
- AbbVie$868
- Otsuka America Pharmaceutical, Inc.$387
- Teva Pharmaceuticals USA, Inc.$360
- Lundbeck LLC$270
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$199
- plus $597 from 8 others
What the payments were for
- Speaking & faculty fees$48,07581%
- Travel & lodging$5,2989%
- Food & beverage$5,95410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 126 | $56,646 |
| AbbVie | 45 | $868 |
| Otsuka America Pharmaceutical, Inc. | 9 | $387 |
| Teva Pharmaceuticals USA, Inc. | 24 | $360 |
| Lundbeck LLC | 11 | $270 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $199 |
| Supernus Pharmaceuticals, Inc. | 8 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $153 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Corium, LLC | 3 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Neurocrine Biosciences, Inc. | 2 | $27 |
| Alkermes, Inc. | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$54,791
- VRAYLAR$451
- REXULTI$220
- QUVIVIQ$125
- Austedo XR$114
How this compares
$59,327 in reported general payments places this provider in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 49 | $58,809 |
| RexultiBrexpiprazole | 12 | $16,411 |
| BelsomraSuvorexant | 15 | $6,344 |
| Bupropion XlBupropion Hcl | 113 | $5,704 |
| Fluvoxamine Maleate | 37 | $1,986 |
| Duloxetine Hcl | 54 | $1,680 |
| Aripiprazole | 37 | $1,449 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 49 | $1,416 |
| Gabapentin | 70 | $1,339 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 36 | $1,272 |
| Lamotrigine | 88 | $1,232 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 31 | $1,148 |
| Lurasidone Hcl | 36 | $1,021 |
| Buspirone Hcl | 54 | $960 |
| Ramelteon | 13 | $953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $56,646 | $58,80949 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $387 | $16,41112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Penfield
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
- Daniel BreeyearNiskayuna$149K
- Elijah StevensBinghamton$131K
- Kayanna JonasFar Rockaway$93K
- Alexis CrisafiFishkill$70K
- Vera ImperialeAlbany$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.